SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

    Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.

    (1) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (2) Plymouth University Medical School, Plymouth, UK.
    (3) Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
    (4) John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
    (5) CHU Dijon - Hôpital d'Enfants, Dijon, France.
    (6) Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
    (7) Institut d'Hématologie de Basse-Normandie, Caen, France.
    (8) Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
    (9) CHU de Rennes, Rennes, France.
    (10) Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
    (11) Clínica Universidad de Navarra, Pamplona, Spain.
    (1)2 Moffitt Cancer Center, Tampa, FL, USA.
    (13) Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
    (14) Border Medical Oncology, Albury, Victoria, Australia.
    (15) Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
    (16) Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (17) Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
    (18) CHU de Nantes-Hotel Dieu, Nantes, France.
    (19) Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
    (20) Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
    (21) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (22) Acerta Pharma, South San Francisco, CA, USA.
    (23) Department of Haematology, Jagiellonian University, Krakow, Poland.

    Leukemia 26 SEPTEMBER 2019

  • The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

    Moreno L (1), Perez C (1), Zabaleta A (1), Manrique I (1), Alignani D (1), Ajona D (1,2,3), Blanco L (1), Lasa M (1), Maiso P (1), Rodriguez I (1), Garate S (1), Jelinek T (1), Segura V (1), Moreno C (1), Merino J (1), Rodriguez-Otero P (1), Panizo C (1), Prosper F (1), San-Miguel JF (1), Paiva B (4).

    (1) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
    (2) Solid Tumors Program, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00443, Pamplona, Spain.
    (3) Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    (4) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.

    Clínical Cancer Research 15 MAY 2019

  • Burkitt-like lymphoma with 11q aberration

    Gonzalez-Farre B (1), Ramis-Zaldivar JE (2), Salmeron-Villalobos J (2), Balagué O (1), Celis V (3), Verdu-Amoros J (4), Nadeu F (2), Sábado C (5), Ferrández A (6), Garrido M (7), García-Bragado F (8), de la Maya MD (9), Vagace JM (9), Panizo CM (10), Astigarraga I (11), Andrés M (12), Jaffe ES (13), Campo E (14), Salaverria I (15).

    (1) Hematopathology Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
    (2) Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
    (3) Pediatric Oncology Department, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.
    (4) Pediatric Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
    (5) Pediatric Oncology Department, Hospital Universitari Vall Hebron, Barcelona, Spain.
    (6) Pathology Department, Hospital Clínico de Valencia, Valencia, Spain.
    (7) Pathology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
    (8) Pathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (9) Pediatric Hematology Department, Hospital Materno Infantil de Badajoz, Badajoz, Spain.
    (10) Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) Pediatrics Department, Hospital Universitario Cruces, Barakaldo, Spain.
    (12) Pediatric Oncology Department, Hospital La Fe, Valencia, Spain.
    (13) Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD.
    (14) Hematopathology Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
    (15) Institut Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    Haematologica 07 FEBRUARY 2019

  • Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms

    Celay J (1), Lozano T (2), Concepcion AR (3,4), Beltrán E (1,5), Rudilla F (2), García-Barchino MJ (1), Robles EF (1), Rabal O (6), de Miguel I (6), Panizo C (7), Casares N (2), Oyarzabal J (6), Prieto J (2,3), Medina JF (3), Lasarte JJ (8), Martínez-Climent JÁ (9).

    (1) Division of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain.
    (2) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
    (3) Division of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
    (4) Department of Pathology, New York University School of Medicine, New York, NY, USA.
    (5) Department of Pharmacology, University of Navarra, Pamplona, Spain.
    (6) Small Molecule Discovery Platform and Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
    (7) Department of Hematology, Clinica Universidad de Navarra, Pamplona, Spain.
    (8) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
    (9) Division of Hematological-Oncology, Center for Applied Medical Research (CIMA), University of Navarra, CIBERONC, IDISNA, Pamplona, Spain 

    Haematologica 01 JUNE 2018

  • Post-transplant lymphoproliferative disease after liver transplantation

    Herrero JI (1), Panizo C (2).

    (1) Medicina Interna, Clínica Universidad de Navarra, España.
    (2) Instituto de Investigación Sanitaria de Navarra (IdiSNA). Pamplona.

    Revista Española de Enfermedades Digestivas 12 JANUARY 2018

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra